BIO 2013 Monday Roundup: Bayer, Orphan Drug Pricing, Avalon/GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
Our survey of news from the first day of BIO 2013 includes a look at Bayer’s business development plans, Avalon Ventures’ tie-up with GlaxoSmithKline, and news from panel discussions on orphan drugs, venture philanthropy and Russia.